JP5970134B2 - 可溶性グアニル酸シクラーゼ活性化因子としてのアルコキシピラゾール - Google Patents

可溶性グアニル酸シクラーゼ活性化因子としてのアルコキシピラゾール Download PDF

Info

Publication number
JP5970134B2
JP5970134B2 JP2015531142A JP2015531142A JP5970134B2 JP 5970134 B2 JP5970134 B2 JP 5970134B2 JP 2015531142 A JP2015531142 A JP 2015531142A JP 2015531142 A JP2015531142 A JP 2015531142A JP 5970134 B2 JP5970134 B2 JP 5970134B2
Authority
JP
Japan
Prior art keywords
compound
electrospray
mmol
alkyl
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015531142A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015527394A5 (enExample
JP2015527394A (ja
Inventor
ジェロッド バーネット ブレンマン
ジェロッド バーネット ブレンマン
ジョン デイヴィッド ジン
ジョン デイヴィッド ジン
マイケル ディー ロウ
マイケル ディー ロウ
クリストファー ロナルド サルコ
クリストファー ロナルド サルコ
エドワード エス タスバー
エドワード エス タスバー
チョンフア チャン
チョンフア チャン
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング, ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2015527394A publication Critical patent/JP2015527394A/ja
Publication of JP2015527394A5 publication Critical patent/JP2015527394A5/ja
Application granted granted Critical
Publication of JP5970134B2 publication Critical patent/JP5970134B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
JP2015531142A 2012-09-07 2013-09-03 可溶性グアニル酸シクラーゼ活性化因子としてのアルコキシピラゾール Active JP5970134B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261697899P 2012-09-07 2012-09-07
US61/697,899 2012-09-07
PCT/US2013/057826 WO2014039434A1 (en) 2012-09-07 2013-09-03 Alkoxy pyrazoles as soluble guanylate cyclase activators

Publications (3)

Publication Number Publication Date
JP2015527394A JP2015527394A (ja) 2015-09-17
JP2015527394A5 JP2015527394A5 (enExample) 2016-02-12
JP5970134B2 true JP5970134B2 (ja) 2016-08-17

Family

ID=49170904

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015531142A Active JP5970134B2 (ja) 2012-09-07 2013-09-03 可溶性グアニル酸シクラーゼ活性化因子としてのアルコキシピラゾール

Country Status (37)

Country Link
US (2) US8906904B2 (enExample)
EP (1) EP2892891B1 (enExample)
JP (1) JP5970134B2 (enExample)
KR (1) KR101692707B1 (enExample)
CN (1) CN104619695B (enExample)
AP (1) AP2015008231A0 (enExample)
AR (1) AR092869A1 (enExample)
AU (1) AU2013312931B2 (enExample)
BR (1) BR112015004529B1 (enExample)
CA (1) CA2880494C (enExample)
CL (2) CL2015000255A1 (enExample)
CY (1) CY1122610T1 (enExample)
DK (1) DK2892891T3 (enExample)
EA (1) EA027244B1 (enExample)
EC (1) ECSP15012804A (enExample)
ES (1) ES2748798T3 (enExample)
GE (1) GEP20176631B (enExample)
HR (1) HRP20191755T1 (enExample)
HU (1) HUE046996T2 (enExample)
IL (1) IL236987A (enExample)
LT (1) LT2892891T (enExample)
MA (1) MA37891B1 (enExample)
MD (1) MD4425C1 (enExample)
MX (1) MX338887B (enExample)
NZ (1) NZ703989A (enExample)
PE (1) PE20151001A1 (enExample)
PH (1) PH12015500457A1 (enExample)
PL (1) PL2892891T3 (enExample)
PT (1) PT2892891T (enExample)
RS (1) RS59394B1 (enExample)
SG (2) SG10201510668UA (enExample)
SI (1) SI2892891T1 (enExample)
TN (1) TN2015000054A1 (enExample)
TW (1) TWI586661B (enExample)
UA (1) UA115881C2 (enExample)
UY (1) UY35012A (enExample)
WO (1) WO2014039434A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2892891T3 (da) * 2012-09-07 2019-10-14 Boehringer Ingelheim Int Alkoxypyrazoler som opløselige guanylatcyklaseaktivatorer
TW201625584A (zh) 2014-07-02 2016-07-16 諾華公司 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
EA032972B1 (ru) * 2014-07-22 2019-08-30 Бёрингер Ингельхайм Интернациональ Гмбх Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
JP2018537488A (ja) 2015-12-18 2018-12-20 ノバルティス アーゲー インダン誘導体、ならびに可溶性グアニル酸シクラーゼ活性化剤としてのその使用
EP3525778A1 (de) 2016-10-11 2019-08-21 Bayer Pharma Aktiengesellschaft Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
EP3498298A1 (en) 2017-12-15 2019-06-19 Bayer AG The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi)
JP7314173B2 (ja) 2018-04-30 2023-07-25 バイエル アクチェンゲゼルシャフト 認知障害の治療のためのｓＧＣ活性化薬及びｓＧＣ刺激薬の使用
BR112020022340A2 (pt) 2018-05-15 2021-02-02 Bayer Aktiengesellschaft benzamidas substituídas por 1,3-tiazol-2-il para o tratamento de doenças associadas com sensibilização de fibras nervosas
US11508483B2 (en) 2018-05-30 2022-11-22 Adverio Pharma Gmbh Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group
WO2020011804A1 (en) * 2018-07-12 2020-01-16 Boehringer Ingelheim International Gmbh Alkoxy pyrazoles as soluble guanylate cyclase activators
EP3911675A1 (en) 2019-01-17 2021-11-24 Bayer Aktiengesellschaft Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
KR20220084347A (ko) * 2019-10-18 2022-06-21 에프엠씨 코포레이션 5-브로모-2-(3-클로로-피리딘-2-일)-2h-피라졸-3-카복실산의 제조 방법
CN112079712B (zh) * 2020-09-18 2022-12-13 江苏美迪克化学品有限公司 一种对乙烯基水杨酸的制备方法
AR124297A1 (es) * 2020-12-10 2023-03-15 Bayer Ag Ácidos pirazol piperidin carboxílicos sustituidos
EP4011873A1 (en) 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
GB202102895D0 (en) 2021-03-01 2021-04-14 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
WO2023183213A1 (en) 2022-03-21 2023-09-28 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators for treating portal hypertension
WO2023237577A1 (en) 2022-06-09 2023-12-14 Bayer Aktiengesellschaft Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women
WO2024097316A1 (en) 2022-11-04 2024-05-10 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators for treating systemic sclerosis
CN120359219A (zh) 2022-12-09 2025-07-22 勃林格殷格翰国际有限公司 Sgc活化剂的固体形式
WO2025036839A1 (en) 2023-08-16 2025-02-20 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators for treating clinically significant portal hypertension and decompensated cirrhosis

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9824310D0 (en) * 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
US20040067938A1 (en) 2000-09-29 2004-04-08 Penglie Zhang Quaternary amines and related inhibitors of factor xa
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
MXPA03004308A (es) 2000-11-22 2003-08-19 Visx Inc Dispositivo de colocacion, accionado por la temperatura, para elementos opticos no lineales.
GB0212785D0 (en) * 2002-05-31 2002-07-10 Glaxo Group Ltd Compounds
AU2003301226A1 (en) 2002-12-20 2004-07-22 Pharmacia Corp Acyclic pyrazole compounds for the inhibition of mitogen activated protein kinase-activated protein kinase-2
EP1906957A1 (en) 2005-07-18 2008-04-09 Bayer HealthCare AG Novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders
US20080045560A1 (en) 2006-08-15 2008-02-21 Wyeth Pyrrolidine and related derivatives useful as PR modulators
EP2144605A1 (en) 2007-05-12 2010-01-20 Bayer HealthCare AG sGC STIMULATORS, sGC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERS
EP2197551B1 (en) * 2007-09-06 2016-12-28 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP2207541B1 (en) * 2007-10-05 2014-10-29 Sanofi-Aventis Deutschland GmbH Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid n-phenylamides in the treatment of pain
WO2009068652A1 (en) 2007-11-30 2009-06-04 Smithkline Beecham Corporation 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators
UY31507A1 (es) * 2007-12-03 2009-07-17 Derivados de piridina activadores de guanilato ciclasa soluble
CA2720343A1 (en) 2008-04-04 2009-10-08 Takeda Pharmaceutical Company Limited Heterocyclic derivative and use thereof
WO2010015652A2 (en) * 2008-08-07 2010-02-11 Smithkline Beecham Corporation Thiazole compounds as activators of soluble guanylate cyclase
WO2010015653A1 (en) * 2008-08-07 2010-02-11 Smithkline Beecham Corporation Pyrimidine derivatives as activators of soluble guanylate cyclase
AU2009322836B2 (en) 2008-11-25 2013-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
MA32967B1 (fr) 2009-01-17 2012-01-02 Bayer Schering Pharma Ag Stimulateurs sgc d'activateurs sgc en combinaison avec des inhibiteurs pde5 dans le traitement du dysfonctionnement érectile
JP5411300B2 (ja) 2009-02-26 2014-02-12 メルク・シャープ・アンド・ドーム・コーポレーション 可溶性グアニレートシクラーゼ活性化剤
WO2011095553A1 (en) 2010-02-05 2011-08-11 Bayer Schering Pharma Aktiengesellschaft Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction
RS54336B1 (sr) * 2010-02-05 2016-02-29 Adverio Pharma Gmbh Sgc stimulatori ili sgc aktivatori, sami za sebe i kombinovani sa pde5 inhibitorima za tretman cistične fibroze
ES2549979T3 (es) * 2010-05-26 2015-11-03 Adverio Pharma Gmbh El uso de estimuladores de la sGC, activadores de la sGC, solos y en combinaciones con inhibidores de la PDE5 para el tratamiento de esclerosis sistémica (EcS)
EP2585055A1 (de) 2010-06-25 2013-05-01 Bayer Intellectual Property GmbH Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen
US8895583B2 (en) 2010-10-28 2014-11-25 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
US8569339B2 (en) 2011-03-10 2013-10-29 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
WO2013025425A1 (en) 2011-08-12 2013-02-21 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
EP2594270A3 (en) 2011-11-18 2013-07-31 BIP Patents The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)
DK2892891T3 (da) * 2012-09-07 2019-10-14 Boehringer Ingelheim Int Alkoxypyrazoler som opløselige guanylatcyklaseaktivatorer

Also Published As

Publication number Publication date
HRP20191755T1 (hr) 2019-12-27
KR101692707B1 (ko) 2017-01-04
LT2892891T (lt) 2020-01-27
AU2013312931A1 (en) 2015-02-05
CL2015000255A1 (es) 2015-05-29
CA2880494A1 (en) 2014-03-13
AP2015008231A0 (en) 2015-01-31
TW201422607A (zh) 2014-06-16
CY1122610T1 (el) 2021-03-12
EA027244B1 (ru) 2017-07-31
PH12015500457B1 (en) 2015-04-20
EA201500298A1 (ru) 2015-08-31
CN104619695A (zh) 2015-05-13
UA115881C2 (uk) 2018-01-10
KR20150048765A (ko) 2015-05-07
AU2013312931B2 (en) 2017-06-22
GEP20176631B (en) 2017-02-27
TN2015000054A1 (en) 2016-06-29
SG10201510668UA (en) 2016-01-28
HUE046996T2 (hu) 2020-04-28
USRE46886E1 (en) 2018-06-05
MX338887B (es) 2016-05-04
ES2748798T3 (es) 2020-03-18
IL236987A (en) 2017-02-28
US20140073629A1 (en) 2014-03-13
CL2015000562A1 (es) 2015-06-12
MX2015002807A (es) 2015-05-15
CA2880494C (en) 2021-09-21
DK2892891T3 (da) 2019-10-14
HK1210164A1 (en) 2016-04-15
WO2014039434A1 (en) 2014-03-13
CN104619695B (zh) 2018-04-10
UY35012A (es) 2014-03-31
BR112015004529A2 (pt) 2017-07-04
RS59394B1 (sr) 2019-11-29
PE20151001A1 (es) 2015-07-15
MA37891A1 (fr) 2018-01-31
SG11201500861QA (en) 2015-04-29
JP2015527394A (ja) 2015-09-17
PT2892891T (pt) 2019-11-05
MA37891B1 (fr) 2018-05-31
PH12015500457A1 (en) 2015-04-20
MD4425C1 (ro) 2017-01-31
EP2892891B1 (en) 2019-07-31
ECSP15012804A (es) 2015-12-31
BR112015004529A8 (pt) 2019-08-27
MD4425B1 (ro) 2016-06-30
US8906904B2 (en) 2014-12-09
PL2892891T3 (pl) 2020-01-31
MD20150019A2 (ro) 2015-07-31
SI2892891T1 (sl) 2019-11-29
AR092869A1 (es) 2015-05-06
TWI586661B (zh) 2017-06-11
BR112015004529B1 (pt) 2022-06-21
EP2892891A1 (en) 2015-07-15
NZ703989A (en) 2017-04-28

Similar Documents

Publication Publication Date Title
JP5970134B2 (ja) 可溶性グアニル酸シクラーゼ活性化因子としてのアルコキシピラゾール
JP6602840B2 (ja) 可溶性グアニル酸シクラーゼの活性化因子としてのヘテロ環式カルボン酸
EP2683710B1 (en) Soluble guanylate cyclase activators
CN112204029B (zh) 治疗性化合物
CN109563103A (zh) 用于治疗或预防与其相关的病症的β-3肾上腺素能受体的调节剂
WO2021197467A1 (zh) 多靶点的抗肿瘤化合物及其制备方法和应用
TW202341987A (zh) 一種Polθ抑制劑
HK1210164B (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
TW202028199A (zh) 作為蛋白激酶抑制劑的萘啶酮和吡啶基嘧啶酮類化合物
HK40006318A (en) Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto
HK40006318B (en) Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto
HK1235056B (zh) Sgc刺激物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150306

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151217

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160516

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160608

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160708

R150 Certificate of patent or registration of utility model

Ref document number: 5970134

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250